Tumor suppression by the extracts of Azadirachta indica (neem) works via anti-proliferation, 22 cell cycle arrest, and apoptosis, demonstrated previously using cancer cell lines and live animal 23 models. However, very little is known about the molecular targets and pathways that the neem 24 extracts and the associated compounds act through. Here, we address this using a genome-wide 25 functional pooled shRNA screen on head and neck squamous cell carcinoma cell line treated with 26 crude neem leaf extracts, known for their anti-tumorigenic activity. By analyzing differences in 27 global clonal sizes of the shRNA-infected cells cultured under no treatment and treatment with 28 neem leaf extract conditions, assayed using next-generation sequencing, we found 225 genes 29 affected the cancer cell growth in the shRNA-infected cells treated with neem extract. Pathway 30 enrichment analyses of whole-genome gene expression data from cells temporally treated with 31 neem extract revealed important roles played by the TGF-β pathway and HSF-1-related gene 32 network. Our results indicate that neem extract simultaneously affects various important molecular 33 signaling pathways in head and neck cancer cells, some of which may be therapeutic targets for this 34 devastating tumor. 35
Introduction 41
Despite previous knowledge on the use of the ethnobotanical database, evidence-based 42 know-how and the mechanism(s) of action of many plant-derived compounds are currently lacking. 43
Azadirachta indica, neem, is one such species that is unique, versatile and important. The neem tree 44 is also one of the most intensively studied sources of natural products with plant-derived extracts 45
showing anti-bacterial, anti-fungal, anti-viral, anti-inflammatory, anti-hyperglycaemic, 46 immunomodulatory, anti-malarial, and anti-carcinogenic properties (reviewed in (Subapriya and 47 Nagini, 2005) . Past efforts on research on neem have mostly been focused on pre-clinical studies, 48 concentrating mainly on two purified neem-derived compounds, nimbolide and azadirachtin, due to 49 their pharmaceutically-and agriculturally-important properties, respectively. The emergence of 50 genome-wide tools and techniques has opened up new avenues to pursue research through 51 systematic studies on cancer drug target discovery using neem-derived metabolites. One such 52 method is RNA interference. It is a powerful and proven system to perturb gene function in higher 53 organisms by phenotypic screening, with potential ability to identify pathways and networks of 54 genes involved in cancer (Tang et libraries of short hairpin RNA (shRNA) coupled with next-generation sequencing offers higher 57 sensitivity and broader dynamic range to screen for biological activity and therefore has the 58 potential to identify the pathways for drug actions through network-based approaches (Erler and 59 Linding, 2010; . 60
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer 61 worldwide (Jemal et al., 2011 ) with a 5-year survival of less than 50% (Mishra and Meherotra, 62 2014 ). In the past, the ability of neem-derived compounds to stop cell proliferation and their 63 mechanism(s) of action have been reported, including in HNSCC cell lines (Roy et al., 2007;  Harish 64 Kumar Kowshik et al., 2017) . However, 66 efforts towards finding novel drug targets and the pathways using genome-wide tools for neem-67 derived compounds is currently lacking. The current study combined genome-wide shRNA based 68 functional screening and whole-genome gene expression assay using a head and neck cancer cell 69 line, paving ways to characterize and understand the critical molecular pathways for the therapeutic 70
properties of the neem leaf extract against HNSCC. 71 72
Materials and Methods 73
Neem plant extracts 74
We tested leaf, bark, fruit, dry seed and twigs from neem plants to make ethanolic extracts. 75
First, the plant parts were collected fresh and thoroughly washed with MilliQ water followed by 70% 76 ethanol and the process was repeated thrice with a final wash with MilliQ water before they were 77 air dried under controlled condition for several days. Once the plant organs were dry, 250gm of 78 each organ was measured and ground separately using a grinder, mixed with 500ml of ethanol and 79 transferred to a glass bottle. The mixture in the glass bottle was rocked overnight to mix thoroughly 80 and then centrifuged at 5000g for 10min. The supernatant was separated, and the residue at the 81 bottom was again treated with 500ml of ethanol with overnight rocking at room temperature 82 followed by centrifugation. The process was repeated three times, and the supernatant was pooled 83 from all the three spins before proceeding to the next step. The ethanolic extract (referred as neem 84 extract) was evaporated using an oven at 55 0 C till the materials became very viscous and gooey like 85 and then kept at 4 0 C until further use. 86 87
Reconstitution of neem extracts 88
Neem extracts were dissolved in DMSO to make a stock solution, which was serially diluted 89 further with Dulbecco's Modified Eagles' Media (DMEM) to make a final concentration of 2mg/ml 90 5 as working stock solution. The working stock solution was passed through a 0. purchased from RIKEN, Japan (Momose et al., 1989) were tested with all neem extracts before 99 HSC-4 was chosen for further study as the cells showed excellent growth inhibitory pattern in the 100 presence of neem extracts. All the cells were maintained in DMEM supplemented with 10% FBS, 101 1X MEM non-essential amino acids solution and 1X penicillin/streptomycin mixture (Gibco) at 102 37 0 C with 5% CO 2 incubation. 103
For IC 50 calculation, the xCELLigence Real-Time Cell Analysis (RTCA) DP instrument 104 (Acea Bio, USA) was used. The device monitors and quantifies cell proliferation, morphology 105 change, and provides an opportunity to observe the quality of cell attachment real-time. HSC-4 cells 106
(1.0 x 10 4 ) were seeded onto wells with varying concentrations of neem extract (25-800µg/ml) for 107 varying times (0-48hrs). The cells were kept under observation, and IC 50 values were calculated for 108 all extracts and those with DMSO only used as vehicle control. Neem leaf extract showed the best 109 dose response ( Fig. S1 ) and therefore chosen for further study. All subsequent experiments were 110 carried out with the IC 50 concentration of neem extract unless otherwise specified. 111 112
Whole genome gene expression assays and data analyses 113
HSC-4 cells were seeded and treated with neem leaf extract (200µg/ml) at nine pre-defined 114 time points (5min, 10min, 15min, 30min, 1hr, 3hr, 6hr, 10hr, and 24hr) and rescued with fresh 115 6 complete medium post 48-hour treatment at these time-points. The samples were assayed for gene 116 expression using Illumina whole-genome HumanHT-12 v4 expression BeadChip (Illumina, San 117 Diego, CA), following the manufacturer's specifications. RNA quality was checked using Agilent 118
Bioanalyzer with RNA Nano6000 chip for integrity before being used in the gene expression assays. 119
The RNA samples were labeled using Illumina TotalPrep RNA Amplification kit (Ambion, USA) 120 and processed following the manufacturer's recommendations. Gene expression data was collected 121 using Illumina's HiScan and analyzed with the GenomeStudio (v2011.1 Gene Expression module 122 1.9.0), and all assay controls were checked to ensure the quality of the assay and chip scanning. (www.cbioportal.org) along with 50 significant most affected genomic profiles (mutations, putative 171 copy number alterations from GISTIC and differentially expressed mRNAs (more than 2-fold) in 172 the TCGA HNSCC dataset (provisional dataset)). Reactome was run by exercising the 'Include 173
Interactors' option to increase the background list of genes. Cancer drugs were mapped to this 174 network while differentiating between the FDA approved ones from those in the pipeline. 175
176
Results 177
IC 50 calculation of the neem extracts on HNSCC cell line HSC-4 178
The IC 50 values for the leaf, bark, fruit, seed and twig extracts were 0.184, 0.226, 2.932, 179 0.530, and 0.283 mg/ml, respectively, and the leaf extract showed the best dose response (Figure 180 S1). Therefore, the leaf extract was used in subsequent experiments at IC 50 concentrations unless 181 otherwise specified. 182 183
Gene expression changes in response to neem extract 184
The overall approach using a combination of functional genomics screening assay with the 185 genome-wide shRNA library and the whole genome expression assay with treatment and rescue 186 conditions is depicted in Figure 1 (Table S2 ) for pathway analysis comprising 15 cancer-related pathways (Table S1) Table 1 . The results from the PCR amplification of the barcodes, in 213 control and treated cells, showed 1369 and 1011 shRNAs with high (ratio versus control: >2) and 214 with low (ratio versus control: <0.5) clonal sizes respectively (Figure 2 ). This represented 149 and 215 10 78 genes, respectively, where more than one shRNA were involved (Table S4 ). The direction of 216 changes in clonal size for genes are described in Table S4 . To globally obtain a set of genes whose 217 function and/or expression were somehow related to the neem extract treatment, we investigated the 218 gene lists from the two independent screening experiments. 219 220 Interaction network of genes and pathways picked from the gene expression and shRNA screening 221 assays 222
We combined the short-listed genes whose expression were significantly changed by the 223 neem extract over at least 4 consecutive time-points (Table S2 ) and those derived from the 224 functional shRNA screening, resulting in a consolidated list of 321 non-redundant genes (Table S5) . 225
These genes were considered to be affected somehow by the neem extract treatment either or both 226 in the functional and/or expression aspects; thus, we further used this list for pathway and 227 interaction network analyses to identify any molecular pathways influenced by the neem extract. 228
The list of 321 genes (Table S5 ) compiled from the combination of the serially up-or down-229 regulated genes across at least four consecutive time-points (3hr, 6hr, 10hr and 24hrs) with large 230 expression change (ratio at least below 0.8 or at least above 1.2) and genes with significant changes 231 in the clonal sizes of shRNA-infected cells in the neem extract treatment, was subjected to pathway 232 enrichment analyses, using Speed and Reactome analysis tools independently. The enrichment 233 analyses using Speed while investigating only the unique set of signature genes resulted in only one 234 pathway, the TGF-β signaling pathway (p = 7.67e-06; FDR = 2.87E-05), with a significant FDR 235 adjusted P value at the 95% level of confidence ( Figure 4A ). The unique genes perturbed in this 236 pathway were TGIF1, SPHK1, DDIT3, RGS16, LRRC15, VDR and GABARAPL1. When all genes 237 in the pathways were investigated, all signalling pathways passed the FDR significance threshold, 238 with MAPK_PI3K signalling pathway at the top, with the least FDR at 3.53e-13 and 18 genes 239 perturbed out of 118 background genes, closely followed by TGF-β at an FDR of 4.69e-13 and 19 240 genes perturbed out of 142 background genes ( Figure 4B ). The pathway enrichment analyses using 241 Reactome resulted in three pathways with significant FDR (< 0.05): Attentuation phase (FDR = 242 3.56e-05), HSF-1-dependent transactivation (FDR = 4.4e-05) and HSF-1 activation (FDR = 0.013) 243 (Table S6 ). The genes over-represented in the Attenuation Phase pathway network were a subset of 244 the two other HSF-1-related pathways; therefore, the HSF-1-related pathway was considered to be 245 the enriched pathway in relation to the neem extract treatment. The perturbed genes common to 246 both HSF-1-related pathways were DNAJB1, HSPA1L, HSPA1A, and DEDD2. HSPB8 was unique 247 to the HSF-1-dependent transactivation pathway network, while RPA1 and RPA2 were unique to the 248 HSF-1 activation pathway. BAG3, PLK1, and SPHK1 were the interactors used in the analysis in the 249 case of HSF-1 activation pathway (Table S6) . 250
251
Identifying potential drug targets for neem extract 252 Finally, we explored any candidate molecular targets that may work in synergy with the 253 neem extract for HNSCC patients. Depending on the list of genes in the pathways which were 254 considered to be related to the mode of actions of neem extract (Figure 4) , we obtained the network 255 and drug target interaction information for the 19 perturbed genes (LRRC15, CITED2, RHOB, 256 TIMP3, GADD45B, TGIF1, PIM1, SPHK1, PTGS2, DDIT3, DUSP1, DDIT4, MIR21, RGS16, 257 HMOX1, HBEGF, EMP1, VDR and GABARAPL1) from the TGF-β signalling pathway as detected 258 by Speed (Parikh et al., 2010) , the 10 genes (DNAJB1, HSPA1L, HSPA1A, DEDD2, HSPB8, RPA1, 259 RPA2, BAG3, PLK1 and SPHK1) from the HSF-1-based pathways as detected by Reactome, (Croft 260 et al., 2014) and the 50 most altered genes for the TCGA HNSCC provisional data from the 261 cBioPortal (Gao et al., 2013) (www.cbioportal.org). A network was drawn using cBioPortal 262 contained 55 nodes, including 16 out of 28 query genes ( Figure 5 ). Thirty-one percent of the 263 network was categorized as 'drug-target interactions'. Among these networks, PTGS2, VDR, RHOB, 264 PIM1, HSPA1L, HSPA1A, and SPHK1 were used as targets for cancer drug development, 12 previously. Out of these, RHOB, VDR, and PTGS2 were the only candidates with FDA-approved 266 anti-cancer drugs, with one each for RHOB and VDR, and 20 for PTGS2 (Table S7 ). For others, 267 quercetin (targeting PIM1) underwent seven clinical trials; and apricoxib (targeting PTGS2) 268 underwent five clinical trials. Other genes such as HMOX1 were the targets of 8 non-anti-cancer 269 non-FDA-approved drugs (Table S7) . the drug mechanisms. In the current study, we combined these two independent global experiments 288 to investigate the molecular mechanisms of the neem extract with focuses on the anti-cancer 289 properties for HNSCC. 290 13 Pathway enrichment analyses were conducted for shortlisted genes which were considered 291 to be differentially affected somehow by the neem extract, either or both in functional and/or gene 292 expression aspects, identifying a possible role for the TGF-β signaling pathway and the HSF-1 293 activation network. The HSF-1 is related to the TGF-β signaling pathway and connects the IGF, 294 TGF-β and cGMP pathways, and controls development processes (Barna et al., 2012 ). The precise 295 molecular interactions and biochemical downstream effects of the neem extract in combination with 296 these pathways remain elusive and will be under a scope in the next research plan. We further raised 297 a list of potential anti-HNSCC drug targets among genes in the TGF-β signaling pathway and/or 298 the HSF-1 activation network (Table S7 ) that may work in synergy with the neem extract against 299 HNSCC. Although the potential effects of these drugs in synergy with the neem extract for HNSCC 300
were not explored in this study, it is highly warranted to confirm their potential applicability in the 301 clinical settings for HNSCC patients. 302
Despite the power of the pooled shRNA library screening, there have been caveats to the 303 shRNA-based drug target discovery, and our study is no exception. Regarding the individual 304 shRNA behavior in the shRNA screening, one would realize some biological discrepancies in 305 comparison with the global gene expression and integrated pathway analyses. For example, 306 although our pathway analyses identified the possible synergic interaction between neem extract 307 and the TGF-β pathway, results from some of the individual hits in the shRNA screening were not 308 concurrent. In the shRNA screening, knockdown of SPHK1 and LRRC15 (both are TGF-β 309 pathway-related genes), for instance, were found to show no and positive effects on the cell growths 310 of HSC-4 cells, respectively, under treatment of neem extract (Table S4 ). It can be hypothesized 311 that the biological effects of the shRNA-mediated inhibition of single gene are heavily influenced 312 by numerous experimental conditions: such as the time-scale (24hr in gene expression and six days 313 in shRNA screening) and chemical activity (long-term culture in shRNA screening may inactivate 314 the extract). One must also consider that single gene inhibition within a global web of signaling 315 14 networks may result in various levels of different biological homeostasis in the cells, resulting in 316 cellular phenotypes different from those expected from the function of the pathway itself. Also, any 317 single gene has multiple of down-stream effectors, possibly influencing both activation and 318 inhibition of cell growth simultaneously. Despite such limitations in our shRNA screening, we 319 identified potential candidate pathways by utilizing an integrated gene set obtained from either or 320 both of the gene expression and/or shRNA screening. This signifies the importance of combining 321 multiple of global datasets and screening hits to identify candidate pathways of drug compounds 322 with broad spectrums of biological effects such as the neem extract. 323
In summary, our study points out that neem leaf extract may offer a therapeutic potential to 324 treat patients with HNSCC through its synergic modulations of pathways via HSF-1 activation and 325 TGF-β signaling. These finding will hopefully help developing novel anti-tumor drugs to be used 326 with the neem leaf extract against HNSCC. 327 328 Table S1 . Expression values for all the genes at various time points and the follow-up rescue 463 experiment along with the fold change statistics and cancer-specific pathways. 464 Table S2 . Genes with altered expression across four or more time points. 465 Table S3 . Results from the PCR amplification of the barcodes, in the control and in the leaf extract 466 treated samples and the ratios representing clonal size changes. 467 
